SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody Provides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation Funding is additional to recent $75m Series B financing DUBLIN and OXFORD, England, April 30, 2024 /PRNewswire/ -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the ...

This dividend stock yields shareholders 10% annually.If you're seeking passive income from your investment portfolio, Hercules Capital (HTGC 0.63%) is one stock that may have caught your attention. Hercules Capital invests in venture-backed start-ups, and offers an ultra-high dividend payout of over 10% annually.However, if you're considering adding Hercules Capital for its passive income potential, there are some things you should know first.Hercules Capital is an ultra-high-yielding company that invests i ...

In the latest market close, Hercules Capital (HTGC) reached $19.07, with a +0.63% movement compared to the previous day. This change lagged the S&P 500's 1.02% gain on the day. At the same time, the Dow added 0.4%, and the tech-heavy Nasdaq gained 2.03%.Shares of the specialty finance company witnessed a gain of 2.71% over the previous month, beating the performance of the Finance sector with its loss of 5.37% and the S&P 500's loss of 3.15%.Analysts and investors alike will be keeping a close eye on the pe ...

Which business development company's stock is better for your portfolio?One type of business that income-focused investors might have come across is the business development company (BDC), which invests in the debt and equity of middle-market companies. However, BDCs can employ very different strategies and not all are created equal.Let's look at two popular BDCs, Hercules Capital (HTGC 1.15%) and PennantPark Investment (PNNT 1.59%), to see which is better for your portfolio. Different approachesHercules Ca ...

Hercules Capital (HTGC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors ofte ...

Stocks that work for billionaires aren't necessarily appropriate for every investor.Investors looking for stocks that can produce heaps of passive income want to look at recent activity from some of the world's most successful investors. Billionaire hedge fund manager Ken Griffin more than tripled Citadel Advisors' position in Hercules Capital (HTGC -1.16%) during the last three months of 2023.Hercules offers a yield that's more than six times the average dividend-paying stock in the benchmark S&P 500 index ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________ FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to___ Commission File No. 814-00702 ___________________________________________________________ ...

Financing the Growth of Tomorrow's Companies Today Q3 2023 INVESTOR PRESENTATION November 2, 2023 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________________________________________ FORM 10-Q _________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 814-00702 ___________________________________ ...

Financial Performance - The company generated record total investment income of $116.2 million, up 61% year-over-year, and record net investment income of $75.7 million, up over 88% year-over-year, equating to $0.53 per share [6][41] - The return on equity reached over 20% for the first time in the company's history [6][41] - The net asset value per share increased to $10.96, representing a 1.3% quarter-over-quarter increase [22][38] Business Line Performance - The company funded debt capital to 19 different companies in Q2, with six being new borrower relationships [7] - Approximately 30% of fundings in the quarter were from unfunded commitments, while 70% came from new commitments, indicating healthy new deal volume [58] - The weighted average internal credit rating improved to 2.24 from 2.26 in Q1, with Grade 1 and 2 credits remaining stable at 59.4% [97] Market Data - Capital raising across the portfolio was strong, with 21 companies raising nearly $1.9 billion in Q2, up over 100% from Q1 [9] - The venture capital ecosystem saw $40 billion in investments in Q2, slightly lower than Q1's $46 billion, but still on track to meet or exceed pre-pandemic levels for 2023 [98] Company Strategy and Industry Competition - The company emphasized diversification in its asset base, managing approximately 50% in technology and 50% in life sciences [29] - The company is optimistic about capturing market share due to the absence of Silicon Valley Bank, which was a dominant player in the market [75][76] - The focus for the second half of 2023 will remain on prudent underwriting and maintaining liquidity [13] Management Commentary on Operating Environment and Future Outlook - Management noted that the venture capital ecosystem remains healthy despite being more selective, with a significant decrease in the number of individual investments [69] - The company expects prepayment activity to remain healthy but decrease to $175 million to $250 million in Q3 [37] - Management expressed confidence in the quality of the loan portfolio, which has led to higher prepayments compared to peers [86] Other Important Information - The company ended Q2 with strong liquidity of over $670 million, which supports both existing portfolio companies and new opportunities [46] - The company raised $65 million through the ATM market, resulting in a $0.07 per share accretion to NAV [25] Q&A Session Summary Question: What is the company's strategy regarding diversification? - The company is managing its asset base at roughly 50% in technology and 50% in life sciences, with plans to adjust based on macro conditions [29] Question: Are there advantages in terms and conditions due to market position? - The company believes it can negotiate better quality deals rather than focusing on tougher deals, maintaining a strong pipeline [10] Question: How is the company responding to changes in the venture capital landscape? - Management noted that while the VC ecosystem is volatile, it remains robust, with significant capital still being deployed [69] Question: What is the outlook for prepayment activity? - The company expects prepayment activity to remain healthy but to decrease in Q3, reflecting the quality of its loan portfolio [37] Question: How does the company view the competitive landscape post-SVB? - Management believes the absence of SVB has created opportunities for market share gains and expects this trend to continue [75][76]